Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · December 20, 2022

Long-Term Clinical Outcomes of a Cohort of Spanish Patients Diagnosed With mRCC With a Complete Response to Sunitinib

Clinical Genitourinary Cancer


Additional Info

Clinical Genitourinary Cancer
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
Clin Genitourin Cancer 2022 Dec 05;[EPub Ahead of Print], G de Velasco, T Alonso-Gordoa, A Rodríguez-Vida, et al

Further Reading